Yuriy Karpenko, Tüzün Gamze, Volodymyr Parchenko, Köse Fadime Aydın, Myroslava Ogloblina, Yıldırım Şuheda, Inna Bushuieva, Kocyigit Umit M, Anastasia Khilkovets, Tüzün Burak, Maryna Parchenko
Department of toxicological and inorganic chemistry, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia 69035, Ukraine.
Deparment of Chemistry, Science Faculty, Sivas Cumhuriyet University, Sivas 58140, Turkey.
Bioorg Chem. 2025 Aug;163:108749. doi: 10.1016/j.bioorg.2025.108749. Epub 2025 Jul 14.
For the past two decades, 1,2,4-triazoles and 1,3,4-oxadiazoles have captured the interest of chemists due to their diverse therapeutic potential, with research primarily guided by the principles of combinatorial chemistry and their broad spectrum of biological activity. The newly synthesized S-derivatives with 1,2,4-triazole and 1,3,4-oxadiazole skeletons were evaluated for cytotoxic activity in human cervical cancer (HeLa), human non-small-cell lung cancer (A-549) and healthy embryonic kidney (HEK-293 T) cell lines. WST-1 assays revealed that only two of the 25 compounds in the series showed significant selective toxicity: Compound 4 exhibited the strongest activity in A-549 cells with an IC₅₀ of 15.65 ± 0.72 μM, while compound 5 showed significant activity in HeLa cells with an IC₅₀ of 24.90 ± 0.62 μM. Both compounds exhibited a cancer-selective profile, with >50 % survival in HEK-293 T cells over the same concentration range. Additionally, the compounds were found to exhibit moderate inhibitory ability (IC₅₀ = 51.72-247.55 μM) against the acetylcholinesterase enzyme; however, these enzyme data are not directly related to cytotoxicity. The in vitro anticholinergic effect of these newly synthesized molecules was investigated and IC values were calculated. Accordingly, IC values were found between 51.72 and 247.55 μM for acetylcholinesterase enzyme activity. To explore Novel 1,2,4-Triazole and 1,3,4-Oxadiazole S-Derivatives at the B3LYP, HF, and M062X levels, Gaussian calculations were performed using the 6-31++g (d,p) basis set. These calculations were carried out in order to analyze the molecules. Calculations using the molecular docking technique were performed on a number of proteins, one of which being the protein that has been linked to cervical cancer (PDB ID: 2EWL and 2OCJ), lung cancer protein (PDB ID: 4ZXT and 5ZMA), and acetylcholinesterase protein (PDB ID: 4M0E). Calculations are performed using the ADME/T approach in order to explore the possible effects and responses that these drugs may have on the metabolism of humans.
在过去二十年中,1,2,4 - 三唑和1,3,4 - 恶二唑因其多样的治疗潜力吸引了化学家的关注,相关研究主要受组合化学原理及其广泛的生物活性指导。对新合成的具有1,2,4 - 三唑和1,3,4 - 恶二唑骨架的S - 衍生物在人宫颈癌(HeLa)、人非小细胞肺癌(A - 549)和健康胚胎肾(HEK - 293 T)细胞系中进行了细胞毒性活性评估。WST - 1分析表明,该系列25种化合物中只有两种显示出显著的选择性毒性:化合物4在A - 549细胞中表现出最强活性,IC₅₀为15.65 ± 0.72 μM,而化合物5在HeLa细胞中表现出显著活性,IC₅₀为24.90 ± 0.62 μM。在相同浓度范围内,两种化合物在HEK - 293 T细胞中的存活率均超过50%,呈现出癌症选择性特征。此外,发现这些化合物对乙酰胆碱酯酶具有中等抑制能力(IC₅₀ = 51.72 - 247.55 μM);然而,这些酶数据与细胞毒性并无直接关联。对这些新合成分子的体外抗胆碱能作用进行了研究并计算了IC值。据此,乙酰胆碱酯酶活性的IC值在51.72至247.55 μM之间。为了 在B3LYP、HF和M062X水平上探索新型1,2,4 - 三唑和1,3,4 - 恶二唑S - 衍生物,使用6 - 31++g(d,p)基组进行了高斯计算。进行这些计算是为了分析分子。使用分子对接技术对多种蛋白质进行了计算,其中一种是与宫颈癌相关的蛋白质(PDB ID:2EWL和2OCJ)、肺癌蛋白质(PDB ID:4ZXT和5ZMA)以及乙酰胆碱酯酶蛋白质(PDB ID:4M0E)。使用ADME/T方法进行计算,以探索这些药物可能对人体新陈代谢产生的影响和反应。